121 related articles for article (PubMed ID: 37883849)
1. Tumor biology, immune infiltration and liver function define seven hepatocellular carcinoma subtypes linked to distinct drivers, survival and drug response.
Wu R; Gao Y; Zhao X; Guo S; Zhou H; Zhang Y; Hou Y; Mei L; Zhi H; Wang P; Li X; Ning S; Zhang Y
Comput Biol Med; 2023 Dec; 167():107593. PubMed ID: 37883849
[TBL] [Abstract][Full Text] [Related]
2. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
3. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
4. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
5. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
Mo Z; Liu D; Rong D; Zhang S
Front Immunol; 2021; 12():611058. PubMed ID: 33679749
[No Abstract] [Full Text] [Related]
6. Comprehensive genomic signature of pyroptosis-related genes and relevant characterization in hepatocellular carcinoma.
Wang S; Gao S; Shan L; Qian X; Luan J; Lv X
PeerJ; 2023; 11():e14691. PubMed ID: 36650832
[TBL] [Abstract][Full Text] [Related]
7. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma.
Liu Z; Zhang Y; Shi C; Zhou X; Xu K; Jiao D; Sun Z; Han X
J Transl Med; 2021 Jan; 19(1):5. PubMed ID: 33407585
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genomic landscape of hepatocellular carcinoma subtypes with various proportions of nonleukocyte stromal cells.
Peng J; Li C; Zhou J; Peng J; Wang C; Lai S; Guo S; Zhong Y; Deng L; Tang X
Gene; 2020 Nov; 761():145028. PubMed ID: 32763490
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations.
Li W; Wu H; Xu X; Zhang Y
Aging (Albany NY); 2021 Apr; 13(8):11564-11594. PubMed ID: 33867349
[TBL] [Abstract][Full Text] [Related]
10. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma.
Li Y; Mo H; Jia S; Wang J; Ma Y; Liu X; Tu K
Front Immunol; 2022; 13():1066773. PubMed ID: 36582227
[TBL] [Abstract][Full Text] [Related]
12. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
Chen X; Hu G; Xiong L; Xu Q
Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
[No Abstract] [Full Text] [Related]
13. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
14. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
15. Identification of molecular heterogeneity of hepatocellular carcinoma based on immune gene expression signatures.
Lou X; Wang JJ; Wei YQ; He YJ; Jiang ZJ; Sun JJ
Med Oncol; 2021 Mar; 38(5):50. PubMed ID: 33786682
[TBL] [Abstract][Full Text] [Related]
16. Immune cell infiltration and immunotherapy in hepatocellular carcinoma.
Jiang Y; Lin L; Lv H; Zhang H; Jiang L; Ma F; Wang Q; Ma X; Yu S
Math Biosci Eng; 2022 May; 19(7):7178-7200. PubMed ID: 35730302
[TBL] [Abstract][Full Text] [Related]
17. An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma.
Yao N; Jiang W; Wang Y; Song Q; Cao X; Zheng W; Zhang J
Eur J Med Res; 2023 Mar; 28(1):123. PubMed ID: 36918943
[TBL] [Abstract][Full Text] [Related]
18. Novel application of the ferroptosis-related genes risk model associated with disulfidptosis in hepatocellular carcinoma prognosis and immune infiltration.
Wei J; Wang J; Chen X; Zhang L; Peng M
PeerJ; 2024; 12():e16819. PubMed ID: 38317842
[TBL] [Abstract][Full Text] [Related]
19. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
[TBL] [Abstract][Full Text] [Related]
20. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
